Navigation Links
Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
Date:9/30/2013

artment of General Surgery, Rush University Medical Center in Chicago. "The fact that this study met the primary endpoint shows the value of continuing to explore the potential of talimogene laherparepvec in regional and distant metastatic melanoma."

The most frequently observed adverse events were fatigue, chills and pyrexia. The most common serious adverse events include disease progression, cellulitis and pyrexia. Serious adverse events occurred in 26 percent of talimogene laherparepvec patients and 13 percent of GM-CSF patients.

Trial Design
This trial was a global, randomized, open-label, Phase 3 trial to evaluate the safety and efficacy of talimogene laherparepvec compared to a control therapy with GM-CSF in over 400 patients with unresected stage IIIB, IIIC or IV melanoma.

Patients were randomized 2:1 to receive either talimogene laherparepvec intralesionally every two weeks or GM-CSF subcutaneously for the first 14 days of each 28 day cycle. Treatment could last for up to 18 months. Where appropriate, stable or responding patients could receive additional treatment on an extension protocol.

About Melanoma
Melanoma is a type of skin cancer that is characterized by the uncontrolled growth of melanocytes, which are the cells responsible for providing pigment to the skin.1 Melanoma is the most aggressive and serious form of skin cancer in which the best treatment approach involves early detection.2 Because it is not always possible to detect cancer in its earlier stage, it can sometimes spread, or metastasize, to other parts of the body.3 The prevalence of metastatic melanoma patients facing recurrence from an earlier stage of disease is predicted to increase by 43 percent by 2015.4 Metastatic melanoma remains a devastating and difficult-to-treat disease with a high unmet need.

Currently, 132,000 melanoma cases occur globally each year.'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen And ShanghaiTech University Announce Plans For Amgen China R&D Center To Open On ShanghaiTech Campus
2. Amgen And Servier Complete Product Collaboration Transaction
3. Amgen Announces 2013 Third Quarter Dividend
4. Technical Briefing: Amgen, PDL BioPharma, Questcor Pharma, and BioCryst Pharma
5. Amgen And Servier Announce Product Collaboration
6. Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations
7. Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting
8. Amgen Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In Melanoma
9. Amgen Announces 2013 Second Quarter Dividend
10. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
11. Amgen Announces Webcast of 2012 Fourth Quarter and Full Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015 Invetech , a ... automation, and contract manufacturing, and  NanoCellect Biomedical, ... and cell sorting technology for life science researchers, ... flow cytometry platform. Headquartered in ... developed a microchip-based cell sorting technology. NanoCellect,s flow ...
(Date:4/21/2015)... -- Tute Genomics, a leading provider of cloud-based genomic medicine technology, ... VP of Marketing. Mr. Forsythe is the latest to join ... commercial operations over the last two quarters. ... is a tremendous addition to the Tute Genomics team," stated ... "Josh,s vast experience commercializing software technology in a highly complex ...
(Date:4/21/2015)... RESEARCH TRIANGLE PARK, N.C. , April 21, 2015 ... announced today that it will release its first quarter ... 28, 2015. United Therapeutics will host a ... a.m. Eastern Time.  The teleconference is accessible by dialing ... the teleconference will be available for one week and ...
(Date:4/21/2015)... Whether it’s used for troubleshooting in a factory, ... Kessler CineDrive in a cinematic studio setting, or ... is designed to help any shooter create vivid high-speed ... the TS5-H offers the same convenient touchscreen controls and streamlined ... According to Tom Boldt for Fastec, “We believe that compelling ...
Breaking Biology Technology:NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 2NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 3Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 2Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 3Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 4Fastec Imaging Releases the TS5-H High Definition High-Speed Camera 2Fastec Imaging Releases the TS5-H High Definition High-Speed Camera 3
... Oct. 11 Generex Biotechnology Corporation (Nasdaq: GNBT ... initiate a rights offering of common stock and warrants to ... a reverse stock split at the reconvened special meeting of ... 2010.  The amount of the offering has not been determined, ...
... for Global Health (BVGH) announced today that G. Steven ... and James A. Geraghty, Senior Vice President, Genzyme Corporation, ... of these two new board members rounds out the ... in emerging markets and public-private partnerships. "Both ...
... PharmaTech (NYSE: WX ), a leading pharmaceutical, ... with operations in China and the United States, today ... Negishi, and Dr. Akira Suzuki on winning the 2010 ... the development of palladium-catalyzed cross coupling, which has vastly ...
Cached Biology Technology:Generex Plans Rights Offering to Stockholders Following Reverse Stock Split 2Generex Plans Rights Offering to Stockholders Following Reverse Stock Split 3Burrill & Company CEO and Genzyme Executive Join BVGH Board of Directors 2Burrill & Company CEO and Genzyme Executive Join BVGH Board of Directors 3WuXi PharmaTech Congratulates the 2010 Nobel Laureates in Chemistry 2
(Date:3/23/2015)... March 23, 2015   HOYOS Labs , a ... today announced that the Company will demonstrate multiple biometrics-based ... and consumers at Connect:ID on March 23 through 25, ... Labs will highlight the IEEE Biometric Open Protocol Standard; ... and enterprise access control system. BOPS was invented by ...
(Date:3/20/2015)... DUBLIN , Mar. 20, 2015 Research ... announced the addition of the "India Sensors ... their offering. The sensor market is ... through 2020 Consumer electronics, automotive, industrial ... for sensors in the country. In addition, adoption ...
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced ... Business Report" report to their offering. This ... Thousands. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... America . Annual estimates and forecasts are ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... drinking water with chlorine boost the chances that pregnant ... of a major new study. If such threats exist ... it concludes. , The national study, directed by University ... earlier, less detailed work done in Northern California and ...
... developed by researchers at the University of Illinois at ... behavior of other molecules. , In previous DNA nanotechnology ... lattice to construct geometrical objects in three dimensions. Instead ... are using DNA to control the folding and resulting ...
... at the Universitat Autònoma de Barcelona has developed new ... same size and thickness as a fingernail and reduce ... minutes or a few hours, depending on each chain. ... ranging from paternity tests and identifying people to detecting ...
Cached Biology News:Major new UNC-based drinking water study suggests pregnancy fears may be overstated 2Major new UNC-based drinking water study suggests pregnancy fears may be overstated 3Health costs soar as 60 million Americans classed as obese 2New miniaturised chip dramatically reduces time taken for DNA analysis 2New miniaturised chip dramatically reduces time taken for DNA analysis 3
...
Practical tool for easy, effective sealing of 0.2ml PCR tubes and plates using cap strips....
Kit for testing the ability of a compound to simulate lipolysis in cultured human adipocytes. Kit contains controls, buffers and reagents for detecting glycerol and non-esterified free fatty acids. A...
... The TRAPeze RT Telomerase Detection ... in vitro assay for the ... quantification of telomerase activity. It ... TRAPeze assay and adds the ...
Biology Products: